Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms

    Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

    Kuvaus

    "Neuropathy is common in patients receiving vinca alkaloids, platinum derivatives, or taxanes. This double-blind, randomized, placebo-controlled study assessed the efficacy of low-dose amitriptyline to relieve chemotherapy-induced symptoms in 44 patients (age 20-65 years) who had neuropathic symptoms (numbness, tingling pain) with a severity of >= 3/10. They were treated with amitriptyline for eight weeks (10 mg/day to start, then dose elevation of 10 mg/week up to 50 mg/day if tolerated, followed, by a stable dose >= 4 weeks). The patients completed a diary twice weekly, noting the intensity of pain, numbness and tingling, global improvement, and adverse effects. Neurological examination, was performed at each visit (baseline, four, and eight weeks). The patients assessed both intensity and relief of pain, and overall discomfort. They also completed the Neuropathic Pain Scale and validated measures of anxiety and depression, and quality of life (QoL). The results demonstrated that amitriptyline did not improve sensory neuropathic symptoms, although there was a trend toward global improvement and improved QoL in favor of the amitriptyline group. No statistical significance was reached, probably due to the small number of patients and too low dose of amitriptyline. Amitriptyline was well tolerated."
    Alkuperäiskielienglanti
    LehtiJournal of Pain and Symptom Management
    Vuosikerta35
    Numero1
    Sivut31-39
    Sivumäärä9
    ISSN0885-3924
    DOI - pysyväislinkit
    TilaJulkaistu - 2008
    OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

    Lainaa tätä

    @article{4c47f88a2f0e41659903b851e330c716,
    title = "Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms",
    abstract = "{"}Neuropathy is common in patients receiving vinca alkaloids, platinum derivatives, or taxanes. This double-blind, randomized, placebo-controlled study assessed the efficacy of low-dose amitriptyline to relieve chemotherapy-induced symptoms in 44 patients (age 20-65 years) who had neuropathic symptoms (numbness, tingling pain) with a severity of >= 3/10. They were treated with amitriptyline for eight weeks (10 mg/day to start, then dose elevation of 10 mg/week up to 50 mg/day if tolerated, followed, by a stable dose >= 4 weeks). The patients completed a diary twice weekly, noting the intensity of pain, numbness and tingling, global improvement, and adverse effects. Neurological examination, was performed at each visit (baseline, four, and eight weeks). The patients assessed both intensity and relief of pain, and overall discomfort. They also completed the Neuropathic Pain Scale and validated measures of anxiety and depression, and quality of life (QoL). The results demonstrated that amitriptyline did not improve sensory neuropathic symptoms, although there was a trend toward global improvement and improved QoL in favor of the amitriptyline group. No statistical significance was reached, probably due to the small number of patients and too low dose of amitriptyline. Amitriptyline was well tolerated.{"}",
    author = "Anna-Liisa Kautio and Maija Haanp{\"a}{\"a} and Tiina Saarto and Eija Kalso",
    year = "2008",
    doi = "10.1016/j.jpainsymman.2007.02.043",
    language = "English",
    volume = "35",
    pages = "31--39",
    journal = "Journal of Pain and Symptom Management",
    issn = "0885-3924",
    publisher = "Elsevier Scientific Publ. Co",
    number = "1",

    }

    Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. / Kautio, Anna-Liisa; Haanpää, Maija; Saarto, Tiina; Kalso, Eija.

    julkaisussa: Journal of Pain and Symptom Management, Vuosikerta 35, Nro 1, 2008, s. 31-39.

    Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

    TY - JOUR

    T1 - Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms

    AU - Kautio, Anna-Liisa

    AU - Haanpää, Maija

    AU - Saarto, Tiina

    AU - Kalso, Eija

    PY - 2008

    Y1 - 2008

    N2 - "Neuropathy is common in patients receiving vinca alkaloids, platinum derivatives, or taxanes. This double-blind, randomized, placebo-controlled study assessed the efficacy of low-dose amitriptyline to relieve chemotherapy-induced symptoms in 44 patients (age 20-65 years) who had neuropathic symptoms (numbness, tingling pain) with a severity of >= 3/10. They were treated with amitriptyline for eight weeks (10 mg/day to start, then dose elevation of 10 mg/week up to 50 mg/day if tolerated, followed, by a stable dose >= 4 weeks). The patients completed a diary twice weekly, noting the intensity of pain, numbness and tingling, global improvement, and adverse effects. Neurological examination, was performed at each visit (baseline, four, and eight weeks). The patients assessed both intensity and relief of pain, and overall discomfort. They also completed the Neuropathic Pain Scale and validated measures of anxiety and depression, and quality of life (QoL). The results demonstrated that amitriptyline did not improve sensory neuropathic symptoms, although there was a trend toward global improvement and improved QoL in favor of the amitriptyline group. No statistical significance was reached, probably due to the small number of patients and too low dose of amitriptyline. Amitriptyline was well tolerated."

    AB - "Neuropathy is common in patients receiving vinca alkaloids, platinum derivatives, or taxanes. This double-blind, randomized, placebo-controlled study assessed the efficacy of low-dose amitriptyline to relieve chemotherapy-induced symptoms in 44 patients (age 20-65 years) who had neuropathic symptoms (numbness, tingling pain) with a severity of >= 3/10. They were treated with amitriptyline for eight weeks (10 mg/day to start, then dose elevation of 10 mg/week up to 50 mg/day if tolerated, followed, by a stable dose >= 4 weeks). The patients completed a diary twice weekly, noting the intensity of pain, numbness and tingling, global improvement, and adverse effects. Neurological examination, was performed at each visit (baseline, four, and eight weeks). The patients assessed both intensity and relief of pain, and overall discomfort. They also completed the Neuropathic Pain Scale and validated measures of anxiety and depression, and quality of life (QoL). The results demonstrated that amitriptyline did not improve sensory neuropathic symptoms, although there was a trend toward global improvement and improved QoL in favor of the amitriptyline group. No statistical significance was reached, probably due to the small number of patients and too low dose of amitriptyline. Amitriptyline was well tolerated."

    U2 - 10.1016/j.jpainsymman.2007.02.043

    DO - 10.1016/j.jpainsymman.2007.02.043

    M3 - Article

    VL - 35

    SP - 31

    EP - 39

    JO - Journal of Pain and Symptom Management

    JF - Journal of Pain and Symptom Management

    SN - 0885-3924

    IS - 1

    ER -